The first month of 2019 is not over yet, but there are already four major announcements about new research projects between large drug discovery corporations and smaller artificial intelligence (AI) companies -- this is more than the number of all similar announcements in the year 2014 combined -- only three.
White Papers And Industry Reports
Updated: 10.01.2019. Newly added content is marked in the text with "Update" sign.
The idea of using artificial intelligence (AI) to accelerate drug discovery process and boost a success rate of pharmaceutical research programs has inspired a surge of activity in this area over the last several years. In 2018, things are getting even “hotter” with the increase in the amount of partnerships, investments and other important events, summarized and grouped below into “mini-trends”.
The deployment of robotics in healthcare to perform complex surgeries with more precision and accuracy has indeed propelled microsurgery robot market trends. Over the last few years robotics is being incorporated prominently in gastrointestinal, gynecological, and urological surgeries, owing to the growing awareness among the healthcare service providers and patients about minimally invasive treatments. Many patients with terminal disorders such as endometrial cancer have also found to be inclined toward robotic techniques. The increasing use of such innovative and minimally invasive medical treatment facilities is slated to fuel microsurgery robot industry size.
Artificial intelligence (AI) has become a hot topic in the biopharmaceutical environment and nearly every pharma company in the world has embraced it hoping that it will play a major role in speeding up drug discovery, by reducing R&D costs and avoiding failure in late development stages. According to prospects, AI-driven drug discovery will lead to the development of new and more effective drugs, paving thus the way to personalized medicine.
In the domain of drug discovery, there can be a world of difference between a computer-generated hit compound, which is predicted to bind well to a drug target and what can be reliably synthesized at scale, or indeed synthesized at all. This discrepancy has been a lingering point of discord between the Discovery and R&D efforts in the chemical industry. Computer-aided drug design (CADD) has become an increasingly valuable tool by providing essential screening data and unique insight into drug action and mechanism, but it does not model the more complex world of chemical reactivity and synthetic chemistry.